Fluocinolone acetonide (FAc) implant in the treatment of retinal angiopathy macular edema in ATTR V30M patients.

IF 2.3 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-06-02 DOI:10.1097/IAE.0000000000004542

Sofia Quintas Cales, Francisca Caiado Bragança, João Heitor Marques, João Magalhães Coelho, Maria João Menéres, João Melo Beirão

{"title":"Fluocinolone acetonide (FAc) implant in the treatment of retinal angiopathy macular edema in ATTR V30M patients.","authors":"Sofia Quintas Cales, Francisca Caiado Bragança, João Heitor Marques, João Magalhães Coelho, Maria João Menéres, João Melo Beirão","doi":"10.1097/IAE.0000000000004542","DOIUrl":null,"url":null,"abstract":"Purpose: to evaluate the effectiveness and safety of the fluocinolone acetonide implant (0.2 µg/day FAc, ILUVIEN®) in macular edema due to retinal amyloid angiopathy (RAA) in patients with hereditary transthyretin amyloidosis associated with the V30M mutation (ATTRV30M).Methods: retrospective observational case series of ATTRV30M patients' eyes treated with the implant for macular edema, from January 2010 to December 2019. Best corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) were measured at baseline, at 1 week, and at months 1, 3, 6, and 12.Results: fifteen eyes of 15 ATTRV30M patients with FAc implants were included. All patients had already received a liver transplant. All had already been submitted to cataract surgery, 87% had an Ahmed valve implant and 80% were vitrectomized due to vitreous amyloidosis. A statistically significant improvement in BCVA and in CFT at all time points was found compared to baseline. There was no statistically significant difference in IOP during the follow-up.Conclusions: patients with macular edema due to RAA treated with the FAc implant showed sustained increased functional results and anatomical improvement compared to baseline.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004542","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: to evaluate the effectiveness and safety of the fluocinolone acetonide implant (0.2 µg/day FAc, ILUVIEN®) in macular edema due to retinal amyloid angiopathy (RAA) in patients with hereditary transthyretin amyloidosis associated with the V30M mutation (ATTRV30M).

Methods: retrospective observational case series of ATTRV30M patients' eyes treated with the implant for macular edema, from January 2010 to December 2019. Best corrected visual acuity (BCVA), central foveal thickness (CFT) and intraocular pressure (IOP) were measured at baseline, at 1 week, and at months 1, 3, 6, and 12.

Results: fifteen eyes of 15 ATTRV30M patients with FAc implants were included. All patients had already received a liver transplant. All had already been submitted to cataract surgery, 87% had an Ahmed valve implant and 80% were vitrectomized due to vitreous amyloidosis. A statistically significant improvement in BCVA and in CFT at all time points was found compared to baseline. There was no statistically significant difference in IOP during the follow-up.

Conclusions: patients with macular edema due to RAA treated with the FAc implant showed sustained increased functional results and anatomical improvement compared to baseline.

查看原文本刊更多论文

氟西诺酮（FAc）植入治疗atr V30M患者视网膜血管性黄斑水肿。

目的：评价氟西诺酮醋酸酯（0.2µg/天FAc， ILUVIEN®）在遗传性甲状腺素转淀粉样变性伴V30M突变（ATTRV30M）患者视网膜淀粉样血管病（RAA）所致黄斑水肿中的有效性和安全性。方法：回顾性观察2010年1月至2019年12月ATTRV30M患者眼部黄斑水肿植入物的病例系列。在基线、第1周、第1、3、6、12个月分别测量最佳矫正视力（BCVA）、中央中央凹厚度（CFT）和眼压（IOP）。结果：纳入15例ATTRV30M患者的15只眼。所有患者都已经接受了肝移植。所有患者都接受了白内障手术，87%的患者接受了艾哈迈德瓣膜植入，80%的患者因玻璃体淀粉样变性而接受了玻璃体切除术。与基线相比，BCVA和CFT在所有时间点均有统计学显著改善。随访期间IOP差异无统计学意义。结论：与基线相比，FAc植入物治疗RAA引起的黄斑水肿患者的功能结果和解剖学改善持续增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.